Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 27, 2022, we reviewed a study published in JACC: Heart Failure that examined the effects of finerenone on heart failure (HF) outcomes by estimated glomerular filtration rate (eGFR) and/or urine albumin-to-creatinine ratio (UACR) categories in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Researchers conducted a pooled analysis of data from the landmark FIDELITY clinical trial program, which included 13 026 participants who had been randomized to finerenone or placebo. They found that use of finerenone was associated with a significantly reduced risk of first hospitalization for heart failure (HHF), cardiovascular (CV) death or first HHF, recurrent HHF, and CV death or recurrent HHF compared to placebo.
“The FIDELITY-HF analysis demonstrates the consistent benefits of finerenone on HF-related outcomes across CKD stages in patients with T2D, regardless of eGFR or UACR at baseline. This reinforces the importance of routine eGFR and UACR screening in clinical practice to ensure early initiation of treatment with finerenone to address cardiovascular risk and morbidity associated with HHF,” the investigators concluded.